Thomas J. Lynch, MD

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses the treatment of patients with

Videos

Thomas J. Lynch, MD, discusses the treatment of patients with T790M-mutant non-small cell lung cancer (NSCLC).

Treating Patients With T790M-Mutant NSCLC

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.

It is important for an oncologist to know when use (or switch) molecular targeted therapies in relation to a patientâ€™s degree of progression.

Dealing with drug side effects remains a challenge. During later lines of treatment, patients are typically less tolerant of side effects.

Thomas J. Lynch, MD, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.

Challenges Associated With Molecular Targeted Therapies in Lung Cancer

Thomas J. Lynch, MD, Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology), director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses actionable mutations in non-small cell lung cancer (NSCLC).

An actionable mutation can be found in 40-45% of patients with NSCLC

Second- and third-generation EGFR inhibitors could have greater efficacy than some older-generation drugs

The range of actionable mutations in NSCLC continues to increase and physicians are now able to find an agent to interact with the specific mutation of the patient

Thomas J. Lynch, MD, Yale Cancer Center, discusses actionable mutations in non-small cell lung cancer (NSCLC).

Thomas J. Lynch, MD | Authors

Articles

Treating Patients With T790M-Mutant NSCLC

Challenges Associated With Molecular Targeted Therapies in Lung Cancer

Actionable Mutations in NSCLC